{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:28:14Z","timestamp":1777336094310,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.euf.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T15:25:32Z","timestamp":1670858732000},"page":"463-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A Systematic Review and Meta-analysis of Chemoablation for Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Takafumi","family":"Yanagisawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsushi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza Sari","family":"Motlagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus von","family":"Deimling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Pallauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Majdoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2022.12.003_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.euo.2021.05.006","article-title":"Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer","volume":"5","author":"Jobczyk","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/modpathol.3800757","article-title":"Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness","volume":"20","author":"Shariat","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euf.2022.12.003_b0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","article-title":"Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature","volume":"65","author":"Crivelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0030","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/cncr.22521","article-title":"Survivin expression is associated with bladder cancer presence, stage, progression, and mortality","volume":"109","author":"Shariat","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2022.12.003_b0035","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","article-title":"Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.12.003_b0040","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.urolonc.2009.07.020","article-title":"Bladder cancer in the elderly","volume":"27","author":"Shariat","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2009.09076.x","article-title":"The effect of age and gender on bladder cancer: a critical review of the literature","volume":"105","author":"Shariat","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.12.003_b0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejso.2013.11.003","article-title":"Transurethral resection of the bladder (TURB): analysis of complications using a modified Clavien system in an Italian real life cohort","volume":"40","author":"De Nunzio","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/21681805.2020.1782978","article-title":"Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study","volume":"54","author":"Erikson","year":"2020","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0060","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/21681805.2016.1201856","article-title":"What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution's experience","volume":"50","author":"Ghali","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0065","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-5347(17)54246-9","article-title":"Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients","volume":"127","author":"Prout","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0070","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2020.07.009","article-title":"The DaBlaCa-13 study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non-muscle-invasive bladder cancer\u2014a randomised controlled trial","volume":"78","author":"Lindgren","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0075","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.12.003_b0080","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.euo.2018.08.032","article-title":"Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non-muscle-invasive bladder cancer","volume":"2","author":"Racioppi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.urology.2020.05.066","article-title":"Chemoablation in urothelial carcinoma: a systematic review and future perspectives","volume":"144","author":"Alsyouf","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.12.003_b0090","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.euf.2022.12.003_b0095","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.euf.2022.12.003_b0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","article-title":"Meta-analysis of proportions using generalized linear mixed models","volume":"31","author":"Lin","year":"2020","journal-title":"Epidemiology"},{"key":"10.1016\/j.euf.2022.12.003_b0105","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2022.12.003_b0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2022.12.003_b0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.euf.2022.12.003_b0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.euf.2022.12.003_b0125","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000473784","article-title":"Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group","volume":"29","author":"Bono","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0130","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","article-title":"Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study","volume":"51","author":"Brausi","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.12.003_b0135","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000331727","article-title":"Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study","volume":"87","author":"Brausi","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2022.12.003_b0140","first-page":"2381","article-title":"Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability","volume":"25","author":"Campodonico","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euf.2022.12.003_b0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a Phase 2b, open-label, single-arm trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0150","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.eururo.2012.05.032","article-title":"Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study","volume":"62","author":"Colombo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0155","first-page":"324","article-title":"Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study","volume":"73","author":"Decaestecker","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.euf.2022.12.003_b0160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Members of the Intravesical Gemcitabine Study Group. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"Gardmark","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.12.003_b0165","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0170","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/j.juro.2017.02.883","article-title":"PD19-10 The chemoablative effect of VesiGel instillation in patients with NMIBC\u2014response rate and 1-year durability","volume":"197","author":"Lenis","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0180","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2006.08.038","article-title":"Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1\u2013G2, low- or intermediate-risk, transitional cell carcinoma of the bladder","volume":"51","author":"Maffezzini","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(01)66552-2","article-title":"Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer","volume":"155","author":"Maffezzini","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1464-410X.1994.tb16585.x","article-title":"Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin","volume":"74","author":"Popert","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","article-title":"Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions","volume":"65","author":"Serretta","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.12.003_b0200","first-page":"199","volume":"29","author":"Van der Meijden","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000052419","article-title":"Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion","volume":"39","author":"Colombo","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0210","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0022-5347(01)66225-6","article-title":"Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer","volume":"155","author":"Colombo","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0215","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","author":"Lindgren","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0220","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/02656736.2014.900194","article-title":"A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer","volume":"30","author":"Sousa","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euf.2022.12.003_b0225","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0230","doi-asserted-by":"crossref","unstructured":"Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007;178(4 Pt 1):1201\u20135; discussion 1205.","DOI":"10.1016\/j.juro.2007.05.148"},{"key":"10.1016\/j.euf.2022.12.003_b0235","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.juro.2017.08.091","article-title":"Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project","volume":"199","author":"Hurle","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0240","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000512052","article-title":"Treatment of large non-muscle-invasive bladder cancer: the potential role of neoadjuvant intravesical chemotherapy","volume":"105","author":"Raber","year":"2021","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2022.12.003_b0245","doi-asserted-by":"crossref","first-page":"775527","DOI":"10.3389\/fsurg.2021.775527","article-title":"Intravesical chemohyperthermia vs. bacillus Calmette-Guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.euf.2022.12.003_b0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fonc.2020.00029","article-title":"Thermal intravesical chemotherapy reduce recurrence rate for non-muscle invasive bladder cancer patients: a meta-analysis","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.euf.2022.12.003_b0255","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.purol.2020.03.005","article-title":"The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: a systematic review","volume":"30","author":"Carando","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0260","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/MOU.0000000000001010","article-title":"Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update","volume":"32","author":"Vartolomei","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0265","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0270","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/JU.0000000000002747","article-title":"Minimal patient-reported side effects for a chemoablative gel (UGN-102) used as frontline treatment in adults with nonmuscle-invasive bladder cancer","volume":"208","author":"Stover","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0275","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.1097\/JU.0000000000002001.13","article-title":"Patient perception of transurethral resection of bladder tumor vs. chemoablation for non-muscle invasive bladder cancer treatment","volume":"206","author":"Parisse","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.12.003_b0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12894-020-00610-9","article-title":"Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial","volume":"20","author":"Li","year":"2020","journal-title":"BMC Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922002875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922002875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:53:24Z","timestamp":1762498404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456922002875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2405456922002875"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2022.12.003","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review and Meta-analysis of Chemoablation for Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}